Antibody for the diagnosis and/or prognosis of cancer
US9120852B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jun 29, 2011 |
| Grant date | Sep 1, 2015 |
| Priority date | — |
| Expiry date | Jan 26, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/565
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to novel antibodies capable of binding specifically to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding process, for detecting and diagnosing pathological hyperproliferative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the over expression of c Met. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.